Esco VacciXcell
Singapore, Singapore· Est.
Singapore‑based provider of single‑use adherent cell bioreactors enabling scalable vaccine and cell‑therapy manufacturing.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Singapore‑based provider of single‑use adherent cell bioreactors enabling scalable vaccine and cell‑therapy manufacturing.
VaccinesCell TherapyGene TherapyBiologics
Technology Platform
Proprietary Tide Motion technology that alternates media submersion and air exposure in a packed‑bed bioreactor to achieve high‑density adherent cell culture with low shear stress.
Opportunities
Rising demand for flexible, single‑use bioreactors in vaccine and cell‑therapy manufacturing offers strong growth potential across Asia‑Pacific and beyond.
Risk Factors
Competition from established bioreactor manufacturers and the need for continuous regulatory compliance could limit market penetration.
Competitive Landscape
Key competitors include Sartorius, Thermo Fisher, and Merck KGaA; Esco VacciXcell differentiates through its Tide Motion low‑shear, scalable adherent‑cell focus.